baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 12/24 GS71/ DE000HD03463 /

16/05/2024 21:46:03	Chg.-0.0800	Bid21:59:15	Ask21:59:15	Underlying	Strike price	Expiration date	Option type
0.9200EUR	-8.00%	0.8700 Bid Size: 4,000	0.9300 Ask Size: 4,000	GSK PLC LS-,3125	19.00 -	18/12/2024	Call

GlobeNewswire 16/05 Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

GlobeNewswire 15/05 Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

GlobeNewswire 13/05 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

GlobeNewswire 10/05 iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 10/05 iTeos Therapeutics Announces $120 Million Registered Direct Offering

GlobeNewswire 09/05 Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 09/05 Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...

GlobeNewswire 09/05 Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...

GlobeNewswire 09/05 Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 09/05 Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

GlobeNewswire 09/05 Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

GlobeNewswire 08/05 SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 08/05 Alector Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08/05 Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...

GlobeNewswire 08/05 Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in ...

GlobeNewswire 07/05 BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Roun...

GlobeNewswire 01/05 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TeleTrader 01/05 British FTSE 100 opens higher amid data, eyes on Fed

TeleTrader 01/05 GSK: Q1 revenue increases 6% to £7.3 billion

GlobeNewswire 30/04 SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the Euro...

GlobeNewswire 30/04 Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial o...

GlobeNewswire 29/04 Immutep Quarterly Activities Report Q3 FY24

GlobeNewswire 25/04 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 23/04 Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and R...

GlobeNewswire 22/04 Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its ...

UC WAR. CALL 12/24 GS71/ DE000HD03463 /

If you wish to receive reply to your feedback, please provide your email address.